Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + RC148 versus nab-paclitaxel alone or nab-paclitaxel + toripalimab in HR-negative HER2-low unresectable locally advanced or metastatic breast cancer
CTR20243539Phase 2Active
- Sponsor
- RemeGen
- Start
- Feb 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, RC148, paclitaxel, toripalimab in breast cancer, sponsored by RemeGen. Started Feb 2025; status: active.
02
Drugs
disitamab vedotinRC148paclitaxeltoripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20243539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243539.